A Phase IIa, Randomised, Double Blind, Placebo Controlled, Three Way Crossover Study to Assess the Pharmacokinetics of RPL554 Administered to Adult Patients With Cystic Fibrosis.

Trial Profile

A Phase IIa, Randomised, Double Blind, Placebo Controlled, Three Way Crossover Study to Assess the Pharmacokinetics of RPL554 Administered to Adult Patients With Cystic Fibrosis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs RPL 554 (Primary)
  • Indications Cystic fibrosis
  • Focus Pharmacokinetics
  • Sponsors Verona Pharma
  • Most Recent Events

    • 27 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
    • 27 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.
    • 04 Apr 2017 According to a Verona Pharma media release, the company expects to announce top-line data from this trial in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top